Drug-Coated Balloons: Who Can Avoid a Heart Stent?

How do drug-coated balloons treat narrowed heart arteries?

Drug-coated balloons combine a mechanical procedure with local drug delivery. After preparing the narrowed segment, the cardiologist inflates a balloon whose coating transfers an antiproliferative medicine, such as paclitaxel, into the artery wall. This medicine suppresses excessive cell growth that can narrow the vessel again. The balloon is then withdrawn, leaving no new metal scaffold at the treatment site. [Clinical expert consensus](https://pmc.ncbi.nlm.nih.gov/articles/PMC10020262/)

A drug-eluting stent also delivers medication, but its metal framework remains to support the artery. A balloon-only approach therefore depends on the vessel staying sufficiently open after treatment. Significant elastic recoil or a tear that restricts blood flow can make a stent necessary. Successful preparation of the narrowed segment is central to deciding whether avoiding an implant is appropriate. [Clinical expert consensus](https://pmc.ncbi.nlm.nih.gov/articles/PMC10020262/)

What does research show about balloons versus heart stents?

University of East Anglia researchers contributed to a systematic review published in BioMed in 2022 that combined 11 studies involving 2,349 patients. It found no statistically significant differences between drug-coated balloons and stents in acute vessel closure, major adverse cardiovascular events or all-cause mortality. These findings support further use and investigation in selected patients. However, failure to detect a difference does not prove that two treatments have identical safety or effectiveness, particularly when estimates are imprecise. This review is earlier evidence, rather than a newly published October study. [UEA research record](https://ueaeprints.uea.ac.uk/id/eprint/92986/)

A larger randomized comparison provides an important counterweight. REC-CAGEFREE I enrolled 2,272 patients with previously untreated coronary narrowing and compared paclitaxel-coated balloon treatment, with rescue stenting when necessary, against planned drug-eluting stents. At three years, the combined outcome of cardiovascular death, heart attack involving the treated vessel or a clinically indicated repeat procedure occurred in 8.2% of the balloon group and 5.0% of the stent group. These are combined event rates, not death rates. [REC-CAGEFREE I three-year results](https://www.jacc.org/doi/10.1016/j.jacc.2025.10.027)

The clinical implication is that avoiding metal must be weighed against durable control of the narrowing. In REC-CAGEFREE I, 9.4% of patients assigned to balloon treatment required a rescue stent during the procedure. Its results argue against routinely replacing planned stenting with this particular balloon strategy across the population studied; they do not resolve every question about other balloon technologies or carefully selected vessel types. [REC-CAGEFREE I three-year results](https://www.jacc.org/doi/10.1016/j.jacc.2025.10.027)

Who can benefit from an approved drug-coated coronary balloon?

The FDA approved the AGENT paclitaxel-coated balloon catheter on February 29, 2024, for coronary in-stent restenosis: narrowing that develops inside a previously implanted stent. That original approval covered appropriately prepared coronary arteries measuring 2.0–4.0 millimeters in diameter and lesions up to 26 millimeters long. This application avoids adding another implant when feasible; it does not remove the stent already present. [FDA approval record](https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pma&id=539032)

The supporting AGENT IDE randomized trial enrolled 600 patients and compared the paclitaxel-coated device with an uncoated balloon. At one year, target-lesion failure occurred in 17.9% versus 28.6%, respectively. This endpoint combined cardiac death, heart attack involving the treated vessel and a repeat procedure for the treated narrowing because of inadequate blood supply. The study demonstrated benefit over an uncoated balloon; it did not compare the device with implantation of another drug-eluting stent or establish a survival benefit. [AGENT IDE trial, JAMA](https://jamanetwork.com/journals/jama/fullarticle/2816073)

For patients, the useful discussion concerns the exact problem being treated: narrowing inside an existing stent, a small previously untreated artery or another coronary lesion. Device-specific evidence, local authorization and the result of vessel preparation all influence the choice. Balloon treatment also requires prescribed follow-up medication; the absence of a new implant does not mean antiplatelet treatment can simply be stopped. [Clinical expert consensus](https://pmc.ncbi.nlm.nih.gov/articles/PMC10020262/)